Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.
Kastelein JJ, Hovingh GK, Langslet G, Baccara-Dinet MT, Gipe DA, Chaudhari U, Zhao J, Minini P, Farnier M. Kastelein JJ, et al. Among authors: farnier m. J Clin Lipidol. 2017 Jan-Feb;11(1):195-203.e4. doi: 10.1016/j.jacl.2016.12.004. Epub 2016 Dec 28. J Clin Lipidol. 2017. PMID: 28391886 Free article. Clinical Trial.
New strategies in the treatment of hypercholesterolemia.
Kastelein J, Farnier M. Kastelein J, et al. Among authors: farnier m. Timely Top Med Cardiovasc Dis. 2005 Oct 17;9:E32. Timely Top Med Cardiovasc Dis. 2005. PMID: 16341285 No abstract available.
PCSK9 inhibitors.
Farnier M. Farnier M. Curr Opin Lipidol. 2013 Jun;24(3):251-8. doi: 10.1097/MOL.0b013e3283613a3d. Curr Opin Lipidol. 2013. PMID: 23652470 Review.
PCSK9: From discovery to therapeutic applications.
Farnier M. Farnier M. Arch Cardiovasc Dis. 2014 Jan;107(1):58-66. doi: 10.1016/j.acvd.2013.10.007. Epub 2013 Dec 27. Arch Cardiovasc Dis. 2014. PMID: 24373748 Free article. Review.
Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.
Kastelein JJ, Robinson JG, Farnier M, Krempf M, Langslet G, Lorenzato C, Gipe DA, Baccara-Dinet MT. Kastelein JJ, et al. Among authors: farnier m. Cardiovasc Drugs Ther. 2014 Jun;28(3):281-9. doi: 10.1007/s10557-014-6523-z. Cardiovasc Drugs Ther. 2014. PMID: 24842558 Free PMC article. Clinical Trial.
Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.
Colhoun HM, Robinson JG, Farnier M, Cariou B, Blom D, Kereiakes DJ, Lorenzato C, Pordy R, Chaudhari U. Colhoun HM, et al. Among authors: farnier m. BMC Cardiovasc Disord. 2014 Sep 20;14:121. doi: 10.1186/1471-2261-14-121. BMC Cardiovasc Disord. 2014. PMID: 25240705 Free PMC article. Clinical Trial.
204 results